Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Caribou Biosciences (CRBU) Invested Capital (2020 - 2025)

Caribou Biosciences has reported Invested Capital over the past 6 years, most recently at $122.2 million for Q4 2025.

  • Quarterly Invested Capital fell 51.7% to $122.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $122.2 million through Dec 2025, down 51.7% year-over-year, with the annual reading at $122.2 million for FY2025, 51.7% down from the prior year.
  • Invested Capital was $122.2 million for Q4 2025 at Caribou Biosciences, down from $141.8 million in the prior quarter.
  • Over five years, Invested Capital peaked at $404.4 million in Q3 2021 and troughed at -$47.7 million in Q2 2021.
  • The 5-year median for Invested Capital is $291.0 million (2022), against an average of $260.2 million.
  • The largest YoY upside for Invested Capital was 3707.18% in 2021 against a maximum downside of 1599.48% in 2021.
  • A 5-year view of Invested Capital shows it stood at $387.8 million in 2021, then fell by 22.42% to $300.9 million in 2022, then grew by 22.44% to $368.4 million in 2023, then tumbled by 31.34% to $253.0 million in 2024, then crashed by 51.7% to $122.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Invested Capital are $122.2 million (Q4 2025), $141.8 million (Q3 2025), and $166.1 million (Q2 2025).